Research advances in neoadjuvant therapy for resectable pancreatic cancer / 国际外科学杂志
International Journal of Surgery
; (12): 843-848, 2021.
Article
em Zh
| WPRIM
| ID: wpr-929954
Biblioteca responsável:
WPRO
ABSTRACT
Pancreatic cancer is highly malignant, and surgical resection is the only cure method at present. In recent years, neoadjuvant therapy has enabled some patients to be successfully downgraded with surgical treatment, which increased the R0 surgical resection rate and prolonged the survival time of patients, has become an important part in the treatment of pancreatic cancer. However, the applicability and standardization of neoadjuvant therapy for pancreatic cancer still need more advanced evidence. This article reviews whether neoadjuvant therapy should be used for resectable pancreatic cancer, the choice of neoadjuvant chemotherapy, and the progress, advantages and disadvantages of neoadjuvant chemoradiotherapy.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
International Journal of Surgery
Ano de publicação:
2021
Tipo de documento:
Article